Key Takeaways
- Expanded Indication: The FDA approved an sBLA expanding ASCENIV to pediatric primary humoral immunodeficiency (PI) patients aged 2–11 years.
- Zero SBIs Recorded: Phase 4 study ADMA-004 met its primary endpoint with zero serious bacterial infections recorded.
- Consistent PK Profile: Trough IgG concentrations remained consistent across age groups and dosing frequencies.
Written By: Anamika Koshti, PharmD
Reviewed By: Pharmacally Editorial Team
The U.S. Food and Drug Administration (FDA) has published detailed clinical, clinical pharmacology and statistical reviews supporting the expansion of ASCENIV (immune globulin intravenous, human-slra) to pediatric patients aged 2 years and older with primary humoral immunodeficiency (PI). The reviews, posted on August 19, 2026, assess data from the Phase 4 ADMA-004 study (NCT05070455) and supportive pediatric data from the earlier ADMA-003 trial.
FDA had already approved the supplemental biologics license application on April 30, 2026, expanding ASCENIV’s indication from patients aged 12 years and older to pediatric patients aged 2 years and older. The newly published reviews provide further detail on the clinical and pharmacological evidence underlying that decision.
ADMA-004 Recorded No Serious Bacterial Infections
ADMA-004 was a prospective, open-label, single-arm, multicenter Phase 4 study conducted to fulfill a Pediatric Research Equity Act postmarketing requirement. The study enrolled 16 children aged 2 to 11 years, who received ASCENIV every three or four weeks at doses of 300 to 800 mg/kg and were followed for approximately five months. Fourteen participants completed treatment.
The primary endpoint was the incidence of acute serious bacterial infections (SBIs). No acute SBIs occurred during the study, meeting the FDA-defined success criterion of fewer than one SBI per patient-year. FDA therefore considered the study successful on its primary endpoint and concluded that it provided substantial evidence of effectiveness.
Seventeen non-serious infections were reported in 10 of the 16 children, with none requiring hospitalization. FDA noted that the approximately five-month observation period was shorter than the 12-month period generally used in its immunoglobulin guidance, but participants were observed across an even distribution of seasons.
IgG Exposure Remained Consistent Across Pediatric Age Groups
The clinical pharmacology review found that IgG trough concentrations remained reasonably consistent across study visits, regardless of age or dosing frequency, indicating maintenance of steady-state concentrations. Based on the available data, ASCENIV clearance appeared comparable across pediatric age groups and similar to adults.
Specific antibody levels against pneumococcal polysaccharide, Haemophilus influenzae type B and respiratory syncytial virus were also maintained between the first and final infusions.
Pediatric Safety Profile Was Consistent with IVIG Products
Fourteen of the 16 children experienced at least one treatment-emergent adverse event, while six experienced events considered at least possibly related to ASCENIV. Two participants discontinued treatment because of adverse events.
An 11-year-old discontinued after nausea, fatigue and headache following the second infusion. A 2-year-old discontinued after a hypersensitivity reaction involving hives and elevated blood pressure. The event was treated with epinephrine, resolved the same day and was classified as a serious adverse event probably related to treatment. A separate serious event of intussusception occurred in a 3-year-old before the first ASCENIV infusion and was considered unrelated to treatment.
No deaths occurred. FDA identified no new safety signals and concluded that the pediatric safety profile was consistent with ASCENIV’s adult experience and other intravenous immunoglobulin products.
ADMA-003 Provided Supportive Pediatric Evidence
FDA also considered pediatric data from ADMA-003, the pivotal study supporting ASCENIV’s original approval. Six participants younger than 12 years were included, and none experienced an acute SBI during 12 months of follow-up.
The FDA review concluded that the combined findings from ADMA-004 and ADMA-003 provided substantial evidence of effectiveness for pediatric patients aged 2 years and older.
FDA Concluded Benefit-Risk Profile Was Favorable
FDA determined that the PREA postmarketing requirement was fulfilled and concluded that the benefit-risk profile of ASCENIV was favorable in the pediatric population studied. The agency’s Pediatric Review Committee agreed with extending the labeling to patients aged 2 years and older.
No additional postmarketing studies or Risk Evaluation and Mitigation Strategy were recommended. FDA considered routine pharmacovigilance appropriate for the product class.
ASCENIV is now indicated for the treatment of primary humoral immunodeficiency in adults and pediatric patients 2 years of age and older. The August FDA publication therefore adds detailed clinical and pharmacological context to the pediatric label expansion approved in April 2026.
References
About the Writer
Anamika Koshti (LinkedIn) is a PharmD professional and healthcare writer with interests in clinical research, pharmacovigilance, and evidence-based medicine. She has authored peer-reviewed publications on Alzheimer’s disease and PCOS, presented research at national conferences, and gained hands-on experience in medical content development and clinical data interpretation. She is committed to translating complex medical research into accurate, accessible content for healthcare professionals and patients.